Literature DB >> 9494762

Hepatic malignancies in childhood and adolescence (hepatoblastoma, hepatocellular carcinoma, and embryonal sarcoma).

E C Douglass1.   

Abstract

Hepatoblastoma is the most common malignant liver tumor of childhood. Clinical trials have demonstrated its responsiveness to chemotherapy, especially with platinum-based chemotherapeutic agents. In patients with completely resected tumors, recurrent disease is effectively controlled by adjuvant chemotherapy. In patients with initially unresectable tumors, chemotherapy can induce tumor shrinkage sufficient to allow complete extirpation of tumor and also to prevent recurrent disease. The child with tumor resistant to primary therapy or with recurrent disease presents a special problem requiring individualized and innovative therapies, including consideration of orthotopic liver transplant. Hepatocellular carcinoma in children and adolescents carries a much poorer prognosis compared to hepatoblastoma. Complete resection of tumor offers the only hope of cure, but these tumors are unfortunately resistant or partially resistant to conventional doses of chemotherapy. A number of innovative treatment strategies have been employed, but optimal treatment remains elusive. Transplant for tumor localized to the liver may offer the only hope of cure. Embryonal (undifferentiated) sarcoma of the liver is a rare tumor that has not been studied prospectively in any clinical trial. Small published series indicate that it can be responsive to chemotherapy, and cure may be possible.

Entities:  

Mesh:

Year:  1997        PMID: 9494762     DOI: 10.1007/978-1-4615-5767-8_7

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  2 in total

1.  Yolk sac tumour of the cryptorchid testis, with an unusual presentation - diagnosed by fine needle aspiration cytology.

Authors:  Dilip Chandra Barman; Aniket Halder; Sumanta Bhattacharya; Krishnendu Mandal; Sanjay Kumar Mallick
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.

Authors:  Hua Yang; Ming Lin; Fuxia Xiong; Yu Yang; Xiu Nie; Michael A McNutt; Rouli Zhou
Journal:  Surg Today       Date:  2011-05-28       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.